ABSTRACT
tion had no effect on the antinociception produced by ␤-endorphin (1 g i.c.v.). However, pretreatment with buprenorphine (0.1-10 g) in mice pretreated with this same dose of ␤-FNA was effective in blocking ␤-endorphin-induced antinociception. ␤-FNA was 226-fold more effective at antagonizing the antinociception induced by DAMGO (16 ng i.c.v.) than by ␤-endorphin (1 g i.c.v.). The antinociception induced by ␦-opioid receptor agonist [D-Ala 2 ]deltorphin II (10 g i.c.v.) or 1 -opioid receptor agonist trans-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl] cyclohexyl)benzeneacetamine methanesulfonate salt [(Ϫ)-U50,488H] (75 g i.c.v.) was not affected by pretreatment with buprenorphine (0.1-1.0 g i.c.v.). It is concluded that buprenorphine, at small doses, blocks ⑀-opioid receptor-mediated ␤-endorphin-induced antinociception and -opioid receptor-mediated DAMGO-induced antinociception, and at high doses produces a -opioid receptor-mediated antinociception.
Buprenorphine, an oripavine derived from thebaine, has widely been shown to be a partial agonist and antagonist of the -opioid receptor, producing both -opioid receptor-mediated antinociception and blocking morphine-induced antinociception in laboratory animals (Cowan et al., 1977; Dum and Herz, 1981; Kamei et al., 1995 Kamei et al., , 1997 . Buprenorphine antagonizes the antinociceptive actions of morphine in the mouse and rat with the tail-flick test, but is not effective in the rat tail-pressure test (Cowan et al., 1977) , and also suppresses and precipitates abstinence in morphine-dependent dogs, mice, monkeys and rats (Martin et al., 1976; Cowan et al., 1977; Dum and Herz, 1981) . Evidence also supports a -opioid antagonism associated with buprenorphine. Buprenorphine shows potent -opioid antagonist properties in the in vitro [
35 S]GTP␥S binding assay (Romero et al., 1999) . Buprenorphine also blocks the -opioid agonist U-50,488H-induced inhibition of abdominal stretching induced by intraperitoneal injection of acetic acid in mice (Leander, 1988) . However, less data are known for the involvement of buprenorphine to stimulate -opioid receptors or to block ␦-opioid receptors, and some findings are contradicting. The antinociception produced by buprenorphine administered intrathecally is blocked by the -opioid antagonist Win 44,441-3 (Tejwani and Rattan, 2002) , whereas buprenorphine given systemically is blocked by pretreatment with selective -opioid receptor antagonist nor-binaltorphimine (Kamei et al., 1995) . Neilan et al. (1999) demonstrate that buprenorphine acts as a ␦-opioid antagonist in the [ 35 S]GTP␥S binding assay using C6 glioma cells expressing the cloned ␦-opioid receptor. On the other hand, no differences were found in the dose-response curves in mice treated with either DPDPE alone, or DPDPE and buprenorphine in the hot water tail-flick technique (Pick et al., 1997) .
Buprenorphine is also identified to exhibit ⑀-opioid receptor binding activity using the nonselective ligand (Ϫ)-[ 3 H]ethylketocyclazocine, in the presence of selective -, ␦-, and 1 -opioid receptor agonists (Nock et al., 1990 (Nock et al., , 1993 Nock, 1995) . Unlike ␤-endorphin, whose affinity to the ⑀-opioid receptor is decreased by high concentration of NaCl, the affinities of buprenorphine to the ⑀-opioid receptor are increased by high concentration of NaCl, suggesting that buprenorpine might be an antagonist for the ⑀-opioid receptor (Nock et al., 1990) . Buprenorphine blocks the increase of [ 35 S]GTP␥S binding induced by ⑀-agonist ␤-endorphin in the pons/medulla membrane obtained from -opioid receptor knockout mice (Mizoguchi et al., 2002) . This finding indicates that buprenorphine acts as an ⑀-opioid receptor antagonist to block the ␤-endorphin-induced G protein activation in the pons/medulla membrane of mice that genetically lack -opioid receptors.
The present study was designed to further characterize the antagonistic properties of buprenorphine for ⑀-and -opioid receptor-mediated antinociception induced by ⑀-opioid receptor agonist ␤-endorphin and -opioid receptor agonist [D-Ala 2 ,N-Me-Phe 4 ,Gly 5 -ol]-enkephalin (DAMGO), in mice. We report here for the first time that buprenorphine blocks ⑀-and -opioid receptor-mediated antinociception induced by i.c.v.-administered ␤-endorphin and DAMGO, respectively. In addition, antinociceptive property induced by high doses of buprenorphine, which is mediated by the stimulation of -opioid receptors, was also characterized.
Materials and Methods
Animals. Male ICR mice, weighing 23 to 25 g (Charles River Laboratories, Inc., Wilmington, MA), were used. Animals were housed five per cage in a room maintained at 22 Ϯ 0.5°C with an alternating 12-h light/dark cycle. Food and water were available ad libitum. Animals were used only once. All experiments were approved by and conformed to the guidelines of the Medical College of Wisconsin Animal Care Committee. Every effort was made to minimize the number and any suffering of animals used in the following experiments.
Assessment of Antinociception. Antinociception was determined by the tail-flick test (D'Amour and Smith, 1941) . For measurement of the latency of the tail-flick response, mice were gently held by hand with their tail positioned in an apparatus (model TF6; EMDIE Instrument Co., Maidens, VA) for radiant heat stimulation on the dorsal surface of the tail. The intensity of heat stimulus was adjusted so that the animal flicked its tail after 3 to 5 s. The inhibition of the tail-flick response was expressed as percent maximum possible effect, %MPE, which was calculated as follows: [(T 1 Ϫ T 0 )/(T 2 Ϫ T 0 )] ϫ 100, where T 0 and T 1 are the tail-flick latencies before and after the treatments, respectively, and T 2 is the cutoff time, set at 10 s to avoid injury of the tail. Intracerebroventricular Injection. Intracerebroventricular injection was performed following the method described by Haley and McCormick (1957) using a 10-l Hamilton syringe. The volume for i.c.v. injection was 4 l.
Drugs. The drugs used were human ␤-endorphin (CalbiochemNovabiochem, San Diego, CA), DAMGO (Bachem California, Torrance, CA), [D-Ala 2 ]deltorphin II (Calbiochem-Novabiochem), ␤-funaltrexamine (␤-FNA; National Institute on Drug Abuse, Baltimore, MD), and (Ϫ)-U50,488H and buprenorphine (Sigma/RBI, Natick, MA). ␤-FNA was dissolved in sterile saline solution. Human ␤-endorphin and DAMGO were dissolved in sterile saline solution containing 0.01% Triton X-100. [D-Ala 2 ]deltorphin II and (Ϫ)-U50,488H were dissolved in sterile saline solution containing 10% (w/v) 2-hydroxypropyl-␤-cyclodextrin (Sigma/RBI). Buprenorphine was dissolved in sterile saline solution containing 0.1% (w/v) dimethyl sulfoxide (DMSO).
Statistical Analysis. The data are expressed as the mean and S.E.M. The ID 50 values were calculated by computer-assisted curvefit program (Prism; GraphPad Software, Inc., San Diego, CA). Statistical analysis of difference between groups was assessed using an F test and one-way or two-way analysis of variance (ANOVA) following Bonferroni's test.
Results
Time Courses of Tail-Flick Responses to i.c.v. Administration of ␤-Endorphin, DAMGO, and Buprenorphine. Groups of mice were injected i.c.v. with various doses of ␤-endorphin (0.3-1 g), DAMGO (5-16 ng), or buprenorphine (1-20 g) and the tail-flick response was measured at various times after the injection. ␤-Endorphin given i.c.v. dose dependently inhibited the tail-flick response. The inhibition of the tail-flick response developed slowly, reached a peak in 10 to 20 min, and the tail-flick latency returned to the preinjection level in 60 min (Fig. 1A) . Similarly, the tail-flick inhibition induced by i.c.v. injection of DAMGO developed slowly, reached a peak in 20 min, and the tail-flick latency returned to the preinjection level 60 min after injection (Fig.  1B) . Buprenorphine given i.c.v. at doses of 3, 10, and 20 g, but not 1 g, also dose dependently inhibited the tail-flick response. The inhibition induced by 10 and 20 g of buprenorphine reached a peak in 10 or 20 min after injection and the tail-flick latency returned to preinjection level within 60 min after injection (Fig. 1C ). Buprenorphine at a low dose (1 g) did not significantly cause any inhibition of the tailflick response. Doses of buprenorphine (up to 1 g) were then used to study the effects of buprenorphine in blocking the tail-flick inhibition induced by ␤-endorphin or DAMGO. In the following experiments, the ␤-endorphin-and DAMGOinduced tail-flick inhibitions were investigated at 20 min after i.c.v. injection of ␤-endorphin or DAMGO.
Effect of i.c.v. Pretreatment with Buprenorphine on the Tail-Flick Inhibition Induced by i.c.v. Administered ␤-Endorphin. Groups of mice were pretreated i.c.v. with buprenorphine (0.001-10 g) or vehicle (0.1% DMSO/ saline, 4 l) 10 min before ␤-endorphin (1 g i.c.v.) administration, and the tail-flick response was measured 20 min after ␤-endorphin administration. Pretreatment with buprenorphine at doses of 0.01 to 1 g dose dependently attenuated the ␤-endorphin-produced tail-flick inhibition. Buprenorphine at 0.1 g markedly reduced the ␤-endorphininduced tail-flick inhibition to 12.7% MPE from 90.5% MPE in the vehicle pretreatment. However, i.c.v. pretreatment with a high dose (10 g) of buprenorphine did not attenuate the tail-flick inhibition induced by ␤-endorphin ( Fig. 2A) .
In another experiment, the effect of pretreatment with 0.1 g of buprenorphine on the tail-flick inhibition induced by various doses of ␤-endorphin (0.1-4 g) was studied. ␤-Endorphin at doses between 0.1 and 4 g given i. jpet.aspetjournals.org the tail-flick inhibition induced by ␤-endorphin and the doseresponse curve for ␤-endorphin-induced tail-flick inhibition was significantly shifted to the right 3.5-fold compared with that of vehicle-pretreated mice ( Fig. 3A ; Table 1 ). Effect of i.c.v. Pretreatment with Buprenorphine on the Tail-Flick Inhibition Induced by i.c.v. Administered DAMGO. Groups of mice were pretreated i.c.v. with buprenorphine (0.001-10 g) or vehicle (0.1% DMSO/saline; 4 l) 10 min before DAMGO (16 ng i.c.v.) injection, and the tail-flick response was measured 20 min after the DAMGO injection. The pretreatment with buprenorphine (0.1 g), but not 0.001, 0.01, or 1 g, significantly attenuated the tail-flick inhibition induced by DAMGO to 22.9% MPE from 70.3% MPE of the control (Fig. 2B) .
In another experiment, the effect of the i.c.v. pretreatment with 0.1 g of buprenorphine on the tail-flick inhibition induced by various doses of DAMGO given i.c.v. was studied. DAMGO at doses between 5 and 40 ng given i.c.v. dose (Fig.  4, A and B) , respectively, and the tail-flick inhibition was measured 20 min after injection. Another group of mice was pretreated i.c.v. with vehicle and challenged with the same dose of ␤-endorphin to serve as controls. The i.c.v. administration of ␤-endorphin (1 g) produced consistent 83 to 91% MPE of the maximum tail-flick inhibition in mice pretreated i.c.v. with vehicle. Pretreatment with 0.1 g of buprenorphine for 10 min, but not 30 min or 1 h, attenuated the ␤-endorphin-induced tail-flick inhibition (Fig. 4A) . On the other hand, pretreatment with 10 g of buprenorphine for 3 h only, but not 10 min, 1 h, 2 h, or 4 h, attenuated the ␤-endorphin-induced tail-flick inhibition (Fig. 4B) .
Effects of i.c.v. Pretreatment with ␤-FNA on the TailFlick Inhibition Induced by i.c.v. Administered ␤-Endorphin, DAMGO, or Buprenorphine.
We have previously demonstrated that i.c.v. pretreatment with ␤-FNA at a dose of 2.5 g for 24 h completely blocks the tail-flick inhibition induced by i.c.v.-administered morphine, but not ␤-endorphin ). The present experiment was extended to determine the relative potency of ␤-FNA, administered i.c.v., for blocking tail-flick inhibition induced by i.c.v.-administered ␤-endorphin and DAMGO. Groups of mice were pretreated i.c.v. with various doses of ␤-FNA 24 h before i.c.v. injection of ␤-endorphin (1 g) or DAMGO (16 ng), and the tail-flick response was measured 20 min after injection. ␤-FNA at 0.001 to 0.1 g and 0.3 to 10 g dose dependently blocked the tail-flick inhibition induced by DAMGO and ␤-endorphin, respectively. ␤-FNA at 0.1 g, which markedly blocked the tail-flick inhibition induced by DAMGO, did not affect the tail-flick inhibition induced by ␤-endorphin. ␤-FNA even at a dose up to 0.3 g did not have any effect on ␤-endorphin-induced tail-flick inhibition. The ID 50 value of ␤-FNA for attenuating the tail-flick inhibition induced by DAMGO and ␤-endorphin was 0.023 and 5.2 g, respectively; ␤-FNA was 226-fold more effective in blocking the antinociception induced by DAMGO than ␤-endorphin (Fig. 5) . ␤-FNA (0.3 g) was then chosen as the dose to use in the following experiment to eliminate the -opioid component of ␤-endorphin antinociception.
Groups of mice were pretreated i.c.v. with ␤-FNA (0.3 g) for 24 h and various doses (0.001-10 g) of buprenorphine for 10 min, and the tail-flick response for i.c.v. administration of 1 g of ␤-endorphin was measured 20 min thereafter. Pretreatment with ␤-FNA (0.3 g) did not have any effect on the tail-flick inhibition induced by 1 g of ␤-endorphin in mice pretreated with saline i.c.v. for 10 min. However, the tailflick inhibition induced by ␤-endorphin was markedly blocked by 0.1 to 10 g of buprenorphine in mice pretreated with ␤-FNA (Fig. 6) .
In another experiment, two groups of mice were pretreated i.c.v. with ␤-FNA (0.3 g) or saline (4 l) 24 h before the i.c.v. -40 ng), and the tail-flick response was measured 20 min after the treatment. The data represent the mean and S.E.M. The ID 50 value was calculated by computer-assisted curve-fit program (Prism). A, the ID 50 value for ␤-endorphin to produce antinociception in mice pretreated with vehicle and buprenorphine was 0.58 and 2.03 g, respectively. The statistical significance of the differences between the groups was assessed with F test. The F value and p value are 13.40 and 0.017, respectively. B, the ID 50 value for DAMGO to produce antinociception in mice pretreated with vehicle and buprenorphine was 12.17 and 23.95 ng, respectively. The statistical significance of differences between the groups was assessed with F test. The F value and p value are 13.46 and 0.003, respectively. (Fig. 7) .
Discussion
The antinociception induced by buprenorphine is mediated by the stimulation of -opioid receptors. Buprenorphine seems to be a -opioid receptor agonist and produces analgesia that is qualitatively similar to that of morphine. We found in the present study that buprenorphine at high doses (3-20 g) given i.c.v. dose dependently produced antinociception in a manner similar to that produced by -opioid agonist DAMGO. The antinociception induced by buprenorphine was completely blocked by the pretreatment with -opioid receptor antagonist ␤-FNA. Our present finding is consistent with the reports of others (Kamei et al., 1995 (Kamei et al., , 1997 ) that the antinociception induced by buprenorphine is mediated by the stimulation of -opioid receptors. Buprenorphine, currently used clinically as an analgesic (Cowan and Lewis, 1995) , is reported to show weaker partial agonistic property for the -opioid receptor in cell membranes expressed with cloned -opioid receptors than morphine or fentanyl (Selley et al., 1997) .
Buprenorphine at Small Doses Blocks Both ⑀-and -Opioid Receptor-Mediated ␤-Endorphin-and DAMGO-Induced Antinociception, Respectively. It has been documented that the antinociception induced by ␤-endorphin given supraspinally is mediated by the stimulation of the ⑀-opioid receptors (for reviews, see Tseng, 1995 Tseng, , 2002 . This view is supported by the finding that the antinociception induced by ␤-endorphin given i.c.v. is not blocked by the pretreatment with the -opioid receptor antagonists D-PheCys-Tyr-Orn-Thr-Pen-Thr-NH 2 or ␤-FNA, the ␦-opioid receptor antagonist naltrindole, or the -opioid receptor antagonist nor-binaltorphimine, but is blocked by the ⑀-opioid receptor antagonist ␤-endorphin(1-27) Suh and Tseng, 1990; Tseng and Collins, 1991; Tseng, 2002) .
␤-Endorphin(1-27) was the only compound previously used as an ⑀-opioid receptor antagonist to characterize the jpet.aspetjournals.org ⑀-receptor properties. We report here for the first time that buprenorphine blocks the ⑀-mediated antinociception induced by i.c.v.-administered ␤-endorphin. We found that antinociception induced by ␤-endorphin given supraspinally was not affected by the pretreatment with -opioid receptor antagonist ␤-FNA (0.3 g), but was effectively blocked by the pretreatment with buprenorphine in mice pretreated with the same dose of ␤-FNA. These findings indicate that buprenorphine blocks the antinociception by blocking the ⑀-opioid receptors stimulated by ␤-endorphin.
We found that the i.c.v. pretreatment with buprenorphine at doses 0.01, 0.1, and 1 g, which given alone did not produce any tail-flick inhibition, effectively and dose dependently attenuated the antinociception induced by i.c.v.-administered ␤-endorphin. In addition, buprenorphine at 0.1 g, but not 0.01 or 1 g, also attenuated the antinociception induced by -opioid receptor agonist DAMGO. Thus, buprenorphine at small doses blocks both ⑀-and -opioid receptors.
Buprenorphine at Doses that Block ⑀-and -Opioid Receptors Does Not Block -and ␦-Opioid Receptors. Pretreatment with these same doses (0.1 and 1 g) of buprenorphine given i.c.v., which blocked antinociception induced by i.c.v.-administered ␤-endorphin or DAMGO, did not affect the antinociception induced by i.c.v. injected ␦-opioid receptor agonist [D-Ala 2 ]deltorphin II or -opioid receptor agonist U50,488H. Our results are consistent with the work done by Pick et al. (1997) showing buprenorphine is unable to block the antinociceptive affects of 1 -opioid agonist U50,488H or ␦-opioid agonist DPDPE. Although other groups have shown -opioid (Leander, 1988; Pick et al., 1997; Romero et al., 1999) and ␦-opioid (Neilan et al., 1999) antagonistic effects with buprenorphine, we simply conclude that buprenorphine given i.c.v. at doses 0.1 to 1 g does not show any significant -or ␦-opioid antagonistic components with the respective agonists we administered. Inconsistency in the literature is possibly due to different subtypes of opioid receptors involved in buprenorphine action, different routes of administration and the receptor density at administration sites, and different efficacy requirements for different experiments.
In conclusion, buprenorphine at high doses produced antinociception, which is mediated by stimulation of Ϫopioid receptors. At low doses, buprenorphine blocked the antinociception induced by ⑀-opioid receptor agonist ␤-endorphin and -opioid receptor agonist DAMGO. 
